Generic Donepezil Costs $552 a Year, Brand Aricept ODT Hits the $2,000 Part D Cap: Comparing Plans Before December 7

Denise isn't related to Margaret. She's the neighbor who started driving her to church on Sundays four years ago, then started noticing the mail piling up, then started managing her pill organizer. Nobody appointed Denise to this job. She just became Margaret's caregiver the way KFF Health News described in "When a Friend Becomes a Caregiver" — one small task at a time, until she was the person standing in the pharmacy line asking why Margaret's dementia medication suddenly cost $180 more than last month.

That question — why did this drug get so much more expensive — is the single most common reason people end up comparing Part D plans. And for caregivers like Denise, who are often managing someone else's medications without the legal standing of a spouse or adult child, the stakes are just as high but the information is harder to get. This post walks through exactly how Margaret's three-drug list prices out across two real plan designs, and what happens to that math the moment one drug switches from generic to brand.

Margaret's drug list

Margaret takes three medications, all commonly prescribed together for dementia with a co-occurring mood disorder:

• Donepezil 10mg (generic Aricept) — once daily
• Memantine 10mg (generic Namenda) — twice daily
• Sertraline 50mg (generic Zoloft) — once daily

All three have long-generic status. Based on Pelandri's analysis of our cms-marketplace-plans dataset (4,080 rows covering plan-level formulary and cost-sharing structures), this combination sits on Tier 1 or Tier 2 in the overwhelming majority of 2026 standalone Part D plans. That should make this an easy, cheap drug list to insure. It usually is — until it isn't.

When the deductible never actually clears

Here's the part most people miss, and it's the first real insight caregivers need: a plan's $0 premium and full deductible can quietly become the cheapest option specifically because your drugs are cheap.

The 2026 standard Part D deductible, per our plan-defaults dataset (30 rows tracking CMS standard benefit parameters), is $590. Under a plan that applies this deductible to every tier — including generics — you pay the pharmacy's full negotiated price until you cross $590 in a calendar year. Look at what Margaret's three generics actually cost at negotiated rates:

Drug	Negotiated monthly cost
Donepezil 10mg (generic)	~$18
Memantine 10mg (generic)	~$22
Sertraline 50mg (generic)	~$6
Total	~$46/month, ~$552/year

Because $552 never reaches the $590 deductible, Margaret never exits the deductible phase. She pays full negotiated price every single month, all year, on a plan we'll call Plan A: $0 premium, full-tier deductible.

	Plan A ($0 premium, deductible on all tiers)	Plan B ($38/mo premium, deductible waived on Tier 1-2)
Annual premium	$0	$456
Deductible phase	Never clears (pays full $552)	Waived for these drugs
Copay phase	N/A	$18/mo × 12 = $216
Total annual cost	$552	$672

Plan A wins by $120 a year — not because it's a "better" plan in general, but because Margaret's specific drug list happens to sit below the deductible threshold, and a plan that waives the deductible on generics has no reason to charge less than negotiated price for those same drugs; it's making up the difference with a premium. This is exactly the kind of interaction that changes completely with a different drug list, which is why comparing Part D plans by your actual medications rather than star ratings matters more than most people realize. This is the kind of analysis Pelandri runs automatically for your specific drug list — so Denise wouldn't need to build this table by hand at 9pm after a pharmacy visit.

What happens when the drug list isn't all-generic anymore

Dementia progresses, and swallowing difficulty is common. If Margaret's care team switches her to Aricept ODT — the brand-name orally disintegrating tablet, because she can no longer reliably swallow the standard tablet — the math above doesn't just shift, it breaks entirely.

Brand Aricept ODT carries a negotiated price around $520/month and typically lands on Tier 4 (non-preferred brand) with 40% coinsurance after the deductible, often requiring prior authorization to confirm the swallowing-difficulty justification. Here's what that does to Plan A, month by month, tracking Margaret's cumulative true out-of-pocket spending (TrOOP) against the 2026 out-of-pocket cap of $2,000:

Month	Running TrOOP	What happens
1	~$548	Full deductible phase, near-full retail price
2	~$788	Deductible clears mid-month, coinsurance begins
3–7	Climbing ~$215/mo	40% coinsurance on Tier 4 + small generic copays
8	Hits $2,000	Catastrophic cap reached
9–12	$0 additional	Plan pays 100% for remainder of year

Margaret hits the $2,000 out-of-pocket cap by roughly month eight. Once she's there, as we've broken down in detail in Medicare's $2,000 Drug Cap Explained, she owes nothing further for covered drugs the rest of the year — on any plan, because the cap is a statutory floor that applies uniformly. That's the second insight, and it flips the entire plan-comparison exercise on its head: once you know a drug list will reach the cap, the plan with the lowest coinsurance percentage stops mattering, and the plan with the lowest premium wins by default.

Run the same math on Plan B: she still hits the $2,000 cap (just a month or two sooner, since Tier 4 cost-sharing there is slightly lower), but she's also paying $456 in premiums Plan A doesn't charge. Total cost: $2,456 versus Plan A's flat $2,000. A $456 difference, driven entirely by premium, because the drug cost itself is capped identically on both plans. This is the same dynamic we've documented with Eliquis, Jardiance, and Entresto combinations reaching catastrophic coverage — the plan with the lower sticker-price premium usually wins once a single expensive brand drug enters the picture, even if its formulary tier structure looks worse on paper.

Before assuming Aricept ODT is unavoidable, it's worth asking the prescriber whether generic donepezil ODT exists in the needed strength, or whether a formulary tier exception can move the brand version to a lower cost-sharing tier — the same exception process we walked through for gabapentin and letrozole users facing high Tier 3 placement.

The Extra Help parallel nobody explains to caregivers

KFF Health News' piece on musicians in Austin — "Nonprofits Are Helping Musicians Pay for Insurance in Austin, Texas, and Beyond" — describes a local nonprofit and public health department stepping in to subsidize marketplace premiums for people whose income falls in an awkward gap: too much to qualify for full assistance, too little to comfortably absorb full-price coverage. Medicare has its own version of that safety net for prescription drugs, and it's dramatically underused: Extra Help, also called the Low-Income Subsidy (LIS).

Based on our aca-subsidy-params dataset, which tracks income and asset thresholds across federal subsidy programs, Extra Help eligibility in 2026 extends to individuals with incomes up to roughly 150% of the federal poverty level and limited assets. For someone in Margaret's situation, full Extra Help eliminates the deductible entirely, caps generic copays around $4-5 and brand copays around $10-12, and removes the premium from the equation on qualifying plans. If Margaret qualifies, that $2,000-cap scenario above could realistically drop below $150 for the year — a gap we've quantified in more detail for Eliquis, metformin, and atorvastatin users navigating Extra Help versus preferred pharmacy pricing. No caregiver should be doing this math without first checking whether the person they're caring for even needs to.

The access problem nobody talks about

There's a reason this analysis matters more for friend-caregivers specifically, and it connects to something KFF Health News flagged in its reporting on the Digital Equity Act ruling. Rural broadband programs designed to help older adults and their informal caregivers get online for exactly this kind of research — comparing plans, checking formularies, requesting tier exceptions — are currently tangled up in litigation, with digital-skills programs paused in several states. If Denise lives in a rural ZIP code without reliable broadband, she can't just casually pull up Medicare Plan Finder on a laptop between errands. She's working from a library computer or a phone call to 1-800-MEDICARE, and every extra hour of friction is an hour she doesn't have, because she's also managing Margaret's medications, appointments, and everything else that comes with an informal caregiving role nobody trained her for.

That's precisely the gap Pelandri is built to close — you can model your own drug list, ZIP code, and pharmacy preference in one pass rather than rebuilding these tables from scratch across a dozen plan PDFs.

Before December 7

Fall Open Enrollment runs through December 7 for coverage effective January 1, 2027. If you're a caregiver — whether you're a spouse, adult child, or simply the friend who ended up in the role, as roughly a third of family and unpaid caregivers nationally are, per census-acs-health-coverage data on informal support networks — this is the window to check three things: whether the current drug list (including any formulation changes like ODT switches) still fits the current plan, whether Extra Help eligibility has ever been checked, and what the actual annual cost comparison looks like once the $2,000 cap and deductible timing are factored in, not just the monthly premium. You can run that comparison for the specific person you're caring for at Pelandri before the enrollment window closes.

Sources

• When a Friend Becomes a Caregiver — KFF Medicare
• Rural Americans Wait After Judge Delivers Mixed Ruling on Digital Equity Dollars — KFF Medicare
• Listen to the Latest ‘KFF Health News Minute’ — KFF Medicare
• A NY Hospital Tried To Close Its Birthing Center. This City United To Fight Back. — KFF Medicare
• Nonprofits Are Helping Musicians Pay for Insurance in Austin, Texas, and Beyond — KFF Medicare